全球智库信息集成服务系统(G2TT): Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets

G2TT

来源类型	Working Paper
规范类型	报告
DOI	10.3386/w26194
来源ID	Working Paper 26194
	Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets
	Rena M. Conti; Ernst R. Berndt
发表日期	2019-09-16
出版年	2019
语种	英语
摘要	We establish four facts concerning competition among U.S. generic drug suppliers, using IQVIA’s National Sales Perspective™ 2004Q4 – 2016Q3 data. We define a unique product market (“molform”), consisting of the combination of a molecule active ingredient and a route of administration formulation, aggregated over different dosages and strengths. We find: (i) supply exhibits substantial churning in entrants and exits; (ii) volume-weighted use concentrates in older generic molform cohorts; (iii) the extent of competition is greatest for the oldest molform cohorts and is smallest for the youngest molform cohorts. With a median of one competitor, the extent of competition in the youngest molform cohort is very limited; and (iv) supplier-molform annual revenues are typically small, are largest for relatively young drugs, but are heavily right skewed. These four facts provide an empirical platform on which to construct and empirically evaluate hypotheses regarding generic drug market structure, performance, and possible policy reforms.
主题	Health, Education, and Welfare ; Health ; Industrial Organization ; Market Structure and Firm Performance ; Industry Studies
URL	https://www.nber.org/papers/w26194
来源智库	National Bureau of Economic Research (United States)
引用统计
资源类型	智库出版物
条目标识符	http://119.78.100.153/handle/2XGU8XDN/583923
推荐引用方式 GB/T 7714	Rena M. Conti,Ernst R. Berndt. Four Facts Concerning Competition in U.S. Generic Prescription Drug Markets. 2019.

条目包含的文件
文件名称/大小	资源类型	版本类型	开放类型	使用许可
w26194.pdf（330KB）	智库出版物		限制开放	CC BY-NC-SA	浏览